Protherics PLC Notification of Major Interests in Shares London, UK; Brentwood, TN, US: 20 November 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, on 19 November 2008, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies ("AXA"). Details of the interest notified are set out below. 1. Reason for the notification (please tick the appropriate box or boxes) An acquisition of voting rights X An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An event changing the breakdown of voting rights Other (please specify) 2. Full name of person(s) subject to the AXA S.A., 25 Avenue notification obligation: Matignon, 75008 Paris and its group of companies. 3. Full name of shareholder(s) (if different from 2.): 4. Date of the transaction (and date on which 18 November 2008 the threshold is crossed or reached if different): 5. Date on which issuer notified: 19 November 2008 6. Threshold(s) that is/are crossed or 12% reached: 7. Notified details: A: Voting rights attached to shares Class/ Situation previous to type of the Triggering shares transaction if Number of Number of possible Shares Voting Rights using the ISIN CODE 0702920 42,026,712 42,026,712 Resulting situation after the triggering transaction Number of Number of voting rights % of voting rights Shares Direct Direct Indirect Direct Indirect 1,041,666 1,041,666 41,322,546 0.30% 11.79% B: Financial Instruments Resulting situation after the triggering transaction Type of Expiration Exercise/ Number of voting rights that % of financial date Conversion may be acquired if the voting instrument Period/ instrument is exercised/ rights Date converted. Total (A+B) Number of voting rights % of voting rights 42,364,212 12.09% 8. Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectively held, if applicable : Name of Company/Fund Number of % of issued share Shares capital AXA 716,666 0.20451 Direct AXA Framlington 41,322,546 11.79204 Indirect AXA IM UK 325,000 0.09274 Direct Total Direct 1,041,666 0.29726 Total Indirect 41,322,546 11.79204 TOTAL 42,364,212 12.08930 Proxy Voting: 9. Name of the proxy holder: 10. Number of voting rights proxy holder will cease to hold: 11. Date on which proxy holder will cease to hold voting rights: 12. Additional information: / Ends / For further information please contact: Protherics Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510 Julie Vickers, Company Secretary +44 (0)1928 518010 Financial Dynamics - press enquiries London: Ben Atwell, Lara Mott +44 (0) 20 7831 3113 New York: John Capodanno +1 212 850 5600 Or visit www.protherics.com This information is provided by RNS The company news service from the London Stock Exchange END
Contact Information: Contacts: RNS Customer Services 0044-207797-4400 http://www.rns.com